Viktoriya Romanovna Ponamareva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Viktoriya Romanovna Ponamareva has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Anna Aleksandrovna Tolkunova
4 shared publications- Irina N. Zakharova
Russian Medical Academy of Continuous Professional Education
4 shared publications Leonid Klimov
4 shared publications- Leonid Yakovlevich Klimov
Stavropol State Medical University
4 shared publications - Liudmila Yur'EVna Barycheva
Stavropol State Medical University; Regional Children’s Clinical Hospital
4 shared publications Svetlana Dolbnya
4 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 60-69
Epithelial‑T‑cell axis cytokines and vitamin D status in different asthma phenotypes in children
Introduction. Bronchial asthma (BA) is a heterogeneous disease that manifests in various phenotypes; identifying these phenotypes allows for the individualization of treatment, which is particularly important among pediatric patients. Aim . To determine the role of IL-17A and IL-33 in identifying bronchial asthma phenotypes in children receiving prophylactic cholecalciferol. Material and methods . A total of 156 children and adolescents from the Stavropol Krai with asthma, aged 13.5 [10.0; 15.9] years, were studied. During the period 2024–2025, a two-stage study of vitamin D status and IL-17A and IL-33 levels was conducted in children against the background of a 3-month intake of an aqueous solution of cholecalciferol at a dose of 1000 IU/day. Results . We identified three main asthma phenotypes in the study group: atopic asthma – 125 (80.1%), non-atopic asthma – 9 (5.8%), and asthma associated with obesity – 22 (14.1%). Statistically significant differences were found only in parameters determining the patients’ phenotypic classification: total IgE level (p = 0.016) and age-adjusted BMI SDS (p < 0.001). No significant differences in serum calcidiol, IL-17A, and IL-33 levels were observed depending on the phenotype. No significant differences in serum calcidiol, IL-17A, and IL-33 levels were observed across phenotypes; however, there was a trend toward lower vitamin D levels and higher cytokine levels as asthma severity increased. Against the background of a prophylactic course of CC medication, a significant increase in vitamin D sufficiency was observed (p < 0.001), which was accompanied by a decrease in IL-17A levels (p = 0.002). No significant effect on IL-33 levels was detected. Conclusion . A three-month course of prophylactic cholecalciferol supplementation leads to a significant reduction in vitamin D deficiency in children and adolescents with asthma and a decrease in IL-17A levels; when combined with standard stepwise therapy, it improves disease control.
- 11 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 60-69
Open AccessEpithelial‑T‑cell axis cytokines and vitamin D status in different asthma phenotypes in children
Introduction. Bronchial asthma (BA) is a heterogeneous disease that manifests in various phenotypes; identifying these phenotypes allows for the individualization of treatment, which is particularly important among pediatric patients. Aim . To determine the role of IL-17A and IL-33 in identifying bronchial asthma phenotypes in children receiving prophylactic cholecalciferol. Material and methods . A total of 156 children and adolescents from the Stavropol Krai with asthma, aged 13.5 [10.0; 15.9] years, were studied. During the period 2024–2025, a two-stage study of vitamin D status and IL-17A and IL-33 levels was conducted in children against the background of a 3-month intake of an aqueous solution of cholecalciferol at a dose of 1000 IU/day. Results . We identified three main asthma phenotypes in the study group: atopic asthma – 125 (80.1%), non-atopic asthma – 9 (5.8%), and asthma associated with obesity – 22 (14.1%). Statistically significant differences were found only in parameters determining the patients’ phenotypic classification: total IgE level (p = 0.016) and age-adjusted BMI SDS (p < 0.001). No significant differences in serum calcidiol, IL-17A, and IL-33 levels were observed depending on the phenotype. No significant differences in serum calcidiol, IL-17A, and IL-33 levels were observed across phenotypes; however, there was a trend toward lower vitamin D levels and higher cytokine levels as asthma severity increased. Against the background of a prophylactic course of CC medication, a significant increase in vitamin D sufficiency was observed (p < 0.001), which was accompanied by a decrease in IL-17A levels (p = 0.002). No significant effect on IL-33 levels was detected. Conclusion . A three-month course of prophylactic cholecalciferol supplementation leads to a significant reduction in vitamin D deficiency in children and adolescents with asthma and a decrease in IL-17A levels; when combined with standard stepwise therapy, it improves disease control.
- Open Access
- 2 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 188-196
Effectiveness of correction of hypovitaminosis D against the background of standard step therapy of bronchial asthma in children
Introduction. The close interest of a wide range of pediatricians in the problems of bronchial asthma (BA) is due to its prevalence, difficulties in selecting basic therapy, and the high frequency of hypovitaminosis D.Aim. To analyze the frequency of vitamin D deficiency and the effectiveness of its correction by including cholecalciferol preparations in the standard step therapy regimen for bronchial asthma in children.Materials and methods. The study involved 75 children and adolescents from the Stavropol Territory suffering from BA, aged12.4 [9.5; 14.8] years. From 2018 to 2021, a two-stage study of vitamin D status was conducted in patients – initially and after completion of a 3-month intake of cholecalciferol aqueous solution (CCF).Results. At the 1st stage of treatment, all 3 (100%) patients were over 12 years old and received low doses of ICS each time they used SABA without constant basic therapy. At the 2nd stage of therapy, all 9 (100%) patients used LRA drugs in age-appropriate dosages. At the 3rd stage, 1 (5.3%) child received treatment with medium doses of ICS, 10 (52.6%) children used a fixed combination of ICS-LABA, and 8 (42.1%) a combination of ICS + LRA.The vitamin D status after taking cholecalciferol preparations increased from 18.3 ng/ml to 35.4 ng/ml. Vitamin D deficiency was initially detected in 44 (58.7%) children, and after the correction course – only in 3 (4.0%) people (p < 0.001).Initially, the median AST was 16.0 [12.0; 20.5] points, and at the end of the study 20.0 [16.0; 24.0] points (p < 0.004).Conclusion. Step therapy for asthma should be prescribed in according to current clinical guidelines. ICS should be used more widely as initial basic therapy for asthma, reducing the number of people receiving monotherapy with ALR.
- 2 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 188-196
Open AccessEffectiveness of correction of hypovitaminosis D against the background of standard step therapy of bronchial asthma in children
Introduction. The close interest of a wide range of pediatricians in the problems of bronchial asthma (BA) is due to its prevalence, difficulties in selecting basic therapy, and the high frequency of hypovitaminosis D.Aim. To analyze the frequency of vitamin D deficiency and the effectiveness of its correction by including cholecalciferol preparations in the standard step therapy regimen for bronchial asthma in children.Materials and methods. The study involved 75 children and adolescents from the Stavropol Territory suffering from BA, aged12.4 [9.5; 14.8] years. From 2018 to 2021, a two-stage study of vitamin D status was conducted in patients – initially and after completion of a 3-month intake of cholecalciferol aqueous solution (CCF).Results. At the 1st stage of treatment, all 3 (100%) patients were over 12 years old and received low doses of ICS each time they used SABA without constant basic therapy. At the 2nd stage of therapy, all 9 (100%) patients used LRA drugs in age-appropriate dosages. At the 3rd stage, 1 (5.3%) child received treatment with medium doses of ICS, 10 (52.6%) children used a fixed combination of ICS-LABA, and 8 (42.1%) a combination of ICS + LRA.The vitamin D status after taking cholecalciferol preparations increased from 18.3 ng/ml to 35.4 ng/ml. Vitamin D deficiency was initially detected in 44 (58.7%) children, and after the correction course – only in 3 (4.0%) people (p < 0.001).Initially, the median AST was 16.0 [12.0; 20.5] points, and at the end of the study 20.0 [16.0; 24.0] points (p < 0.004).Conclusion. Step therapy for asthma should be prescribed in according to current clinical guidelines. ICS should be used more widely as initial basic therapy for asthma, reducing the number of people receiving monotherapy with ALR.
- Open Access
- 7 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 119-129
The effect of cholecalciferol subsidies on the level of pro-inflammatory cytokines in children with bronchial asthma
Introduction. Currently, there are insufficient studies to demonstrate the effect of vitamin D status on the production of proinflammatory cytokines in children with allergic diseases, which precipitated this study.Aim. To analyse interferon-γ, interleukin-17A and 33 profiles in children with asthma according to serum calcidiol levels before and during cholecalciferol subsidies.Materials and methods. A total of 71 children aged 3 to 18 years were examined: 51 patients with asthma and 20 children in the control group. A 3-month cholecalciferol course at a prophylactic dose specified in the national program was prescribed to all children. 25(OH)D, interferon-γ, interleukin-17A and 33 levels were twice determined in the examined children.Results and discussion. Median 25(OH)D levels in patients with asthma did not reach the levels of healthy children either before or after cholecalciferol subsidies at prophylactic doses. Vitamin D intake led to a decrease in interferon-γ levels in healthy children from 3.07 [2.29; 4.81] pg/ml to 2.18 [1.74; 3.45] pg/ml (p < 0.05). In patients with asthma, such changes were not detected in the initial population, however, after cholecalciferol subsidies their interferon-γ levels were significantly higher than those in healthy children: 3.11 [0.89; 5.0] pg/ml and 2.18 [1.74; 3.45] pg/ml, respectively (p < 0.05). Assessment results of interleukin-17A levels in children with asthma showed that the median cytokine levels were significantly higher before the cholecalciferol subsidies than after them: 2.03 [0.1; 10.01] pg/ml and 0.96 [0.1; 12.87] pg/ml, respectively (p = 0.03). The median interleukin-17A levels in children with asthma were significantly higher than in healthy children, both before and during the cholecalciferol subsidies. The median interleukin-33 levels were significantly higher in children with asthma as compared to healthy children, both before and during vitamin D subsidies.Conclusion. Our results suggest that cholecalciferol has a modulatory effect on interferon-γ and interleukin-17A in patients with asthma. Interleukin-33 levels did not change significantly in children with asthma on cholecalciferol.
- 7 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 119-129
Open AccessThe effect of cholecalciferol subsidies on the level of pro-inflammatory cytokines in children with bronchial asthma
Introduction. Currently, there are insufficient studies to demonstrate the effect of vitamin D status on the production of proinflammatory cytokines in children with allergic diseases, which precipitated this study.Aim. To analyse interferon-γ, interleukin-17A and 33 profiles in children with asthma according to serum calcidiol levels before and during cholecalciferol subsidies.Materials and methods. A total of 71 children aged 3 to 18 years were examined: 51 patients with asthma and 20 children in the control group. A 3-month cholecalciferol course at a prophylactic dose specified in the national program was prescribed to all children. 25(OH)D, interferon-γ, interleukin-17A and 33 levels were twice determined in the examined children.Results and discussion. Median 25(OH)D levels in patients with asthma did not reach the levels of healthy children either before or after cholecalciferol subsidies at prophylactic doses. Vitamin D intake led to a decrease in interferon-γ levels in healthy children from 3.07 [2.29; 4.81] pg/ml to 2.18 [1.74; 3.45] pg/ml (p < 0.05). In patients with asthma, such changes were not detected in the initial population, however, after cholecalciferol subsidies their interferon-γ levels were significantly higher than those in healthy children: 3.11 [0.89; 5.0] pg/ml and 2.18 [1.74; 3.45] pg/ml, respectively (p < 0.05). Assessment results of interleukin-17A levels in children with asthma showed that the median cytokine levels were significantly higher before the cholecalciferol subsidies than after them: 2.03 [0.1; 10.01] pg/ml and 0.96 [0.1; 12.87] pg/ml, respectively (p = 0.03). The median interleukin-17A levels in children with asthma were significantly higher than in healthy children, both before and during the cholecalciferol subsidies. The median interleukin-33 levels were significantly higher in children with asthma as compared to healthy children, both before and during vitamin D subsidies.Conclusion. Our results suggest that cholecalciferol has a modulatory effect on interferon-γ and interleukin-17A in patients with asthma. Interleukin-33 levels did not change significantly in children with asthma on cholecalciferol.
- Open Access
- 26 February 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 72-81
Vitamin D supply, respiratory viral infections and persistent wheezing in children: how significant is the relationship?
The review discusses the multifaceted effect of vitamin D on antiviral immunity, induction of antimicrobial peptides, functional activity of immunocompetent cells, autophagy processes, clearance of viruses and viral fragments. The relationship between vitamin D and allergic inflammatory cells, its modulating and tolerogenic potential is considered. The inhibitory effect of vitamin D on eosinophils, mast cells, the production of pro-inflammatory and proallergic mediators, and the synthesis of IgE has been shown. The protective role of vitamin D in the development of remodeling and hyperresponsiveness of the respiratory tract has been established by reducing the number of goblet cells, mucus hypersecretion, and the expression of metalloproteinases. The effects of vitamin D on the replication of respiratory viruses and experimental resistance to them through the induction of antimicrobial peptides and other mechanisms have been demonstrated. Data from clinical studies on the preventive effect of vitamin D on the incidence of respiratory infections and episodes of persistent wheezing in children are presented. Children with respiratory syncytial infection and vitamin D deficiency were more likely to require respiratory support and mechanical ventilation. The preventive role of vitamin D in the development of obstructive bronchitis in children and severe bronchiolitis in infants has been shown. It has been established that normal levels of 25(OH)D in the mother significantly reduce the risk of developing bronchial obstruction in the child. Alternative data that do not support a protective effect of vitamin D on respiratory morbidity and wheezing in children are discussed. Further monitoring studies that take into account geographic location and analysis of the dose of cholecalciferol used to assess its preventive role in the development of wheezing and bronchial asthma in children are advisable.
- 26 February 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 1,p. 72-81
Open AccessVitamin D supply, respiratory viral infections and persistent wheezing in children: how significant is the relationship?
The review discusses the multifaceted effect of vitamin D on antiviral immunity, induction of antimicrobial peptides, functional activity of immunocompetent cells, autophagy processes, clearance of viruses and viral fragments. The relationship between vitamin D and allergic inflammatory cells, its modulating and tolerogenic potential is considered. The inhibitory effect of vitamin D on eosinophils, mast cells, the production of pro-inflammatory and proallergic mediators, and the synthesis of IgE has been shown. The protective role of vitamin D in the development of remodeling and hyperresponsiveness of the respiratory tract has been established by reducing the number of goblet cells, mucus hypersecretion, and the expression of metalloproteinases. The effects of vitamin D on the replication of respiratory viruses and experimental resistance to them through the induction of antimicrobial peptides and other mechanisms have been demonstrated. Data from clinical studies on the preventive effect of vitamin D on the incidence of respiratory infections and episodes of persistent wheezing in children are presented. Children with respiratory syncytial infection and vitamin D deficiency were more likely to require respiratory support and mechanical ventilation. The preventive role of vitamin D in the development of obstructive bronchitis in children and severe bronchiolitis in infants has been shown. It has been established that normal levels of 25(OH)D in the mother significantly reduce the risk of developing bronchial obstruction in the child. Alternative data that do not support a protective effect of vitamin D on respiratory morbidity and wheezing in children are discussed. Further monitoring studies that take into account geographic location and analysis of the dose of cholecalciferol used to assess its preventive role in the development of wheezing and bronchial asthma in children are advisable.
- 1 January 2024
- Published by Stavropol State Medical University in Medical news of the North Caucasus
- Vol. 19 (2)
Bone metabolism status in children with chronic respiratory diseases
- 1 January 2024
- Published by Stavropol State Medical University in Medical news of the North Caucasus
- Vol. 19 (2)
Bone metabolism status in children with chronic respiratory diseases